Related Experiment Video
Updated: Jul 22, 2026
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
[A case report of TS-1 in a patient with advanced gastric cancer]
Y Takahashi1, H Tomita, K Yasuda
1Dept. of Surgery, Gifu Prefectural Hospital.
Abstract:
TS-1 is an oral anticancer drug that produces biochemical modulation. TS-1 is composed of FT (tegafur), CDHP (gimestat, which inhibits 5-FU degradation enzyme), and Oxo (otastat potassium, which reduces 5-FU gastrointestinal toxicities), in a molar ratio of 1:0.4:1. We administered TS-1 to a 68-year-old female gastric cancer patient, after distal gastrectomy (Stage IV, cur C). As a result of abdominal CT, the diameter of metastatic lymph node increased before and after surgery, and before TS-1 (45 x 35 mm), but it was reduced after 1 course of TS-1 (37 x 25 mm), 2 courses of TS-1 (35 x 20 mm), 3 courses of TS-1 (30 x 20 mm), 4 courses of TS-1 (30 x 20 mm), and 6 months after 4 courses of TS-1 (20 x 20 mm). The reduction rate is 74.6%. The value of CA125 was reduced 74.4 to 8.6 after TS-1. Anorexia and back pain, which occurred after operation, disappeared after TS-1. There was no side effect over grade 3.
Insights
This study shows TS-1, an oral anticancer drug, effectively reduced gastric cancer metastasis by 74.6% in a patient. The treatment also improved tumor markers and relieved pain with minimal side effects.
Area of Science:
- Oncology
- Pharmacology
Background:
- TS-1 is an oral anticancer drug comprising tegafur (FT), gimestat (CDHP), and otastat potassium (Oxo).
- CDHP inhibits 5-fluorouracil (5-FU) degradation, while Oxo mitigates 5-FU's gastrointestinal toxicity.
Observation:
- A 68-year-old female patient with Stage IV gastric cancer received TS-1 post-distal gastrectomy.
- Abdominal CT revealed a significant reduction in metastatic lymph node size from 45x35 mm to 20x20 mm after TS-1 treatment.
- Tumor marker CA125 decreased from 74.4 to 8.6, and post-operative anorexia and back pain resolved.
Findings:
- TS-1 treatment resulted in a 74.6% reduction in metastatic lymph node diameter.
- Significant decrease in serum CA125 levels observed.
- Resolution of treatment-related symptoms including anorexia and back pain.
Implications:
- TS-1 demonstrates potent efficacy in managing advanced gastric cancer.
- The drug offers a favorable safety profile with no side effects over grade 3.
- TS-1 represents a promising therapeutic option for gastric cancer patients.
